StockNews.AISignal intelligence
Omeros Corporation · NASDAQ · Healthcare
Browse public OMER signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Cantor Fitzgerald upgrades OMER to Overweight with a $22 target after Yartemlea's stronger-than-expected launch. Payer support via NTAP and a J-code, plus Q2 revenue of $28.5M (up 11% sequentially), bolster long-term adoption and peak sales potential. The stock rose about 12%, signaling potential further upside.
View signal analysisEMA CHMP cited trial design flaws and limited pediatric data for Yartemlea TA-TMA, limiting interpretability. Despite FDA approval and a US launch, EMA concerns could slow European uptake. CMS J-code set for July 1, 2026 and NTAP prospects support US reimbursement, but the EMA setback keeps OMER under pressure.
View signal analysisOMER prices its new drug at $36,000 per single-dose vial. The drug targets a life-threatening transplant complication for adults and children.
View signal analysisOMER's drug receives FDA approval for a dangerous transplant complication. This marks the first treatment approved specifically for this condition.
View signal analysisOmeros Corporation's stock rose over 150%. They secured a $2.1 billion deal with Novo Nordisk. The deal is for the MASP-3 inhibitor, zaltenibart. Investor confidence improved, alleviating bankruptcy fears. Continued operations now supported for Omeros Corporation.
View signal analysisH.C. Wainwright rates OMER as Buy with a $9 price target. Omeros approaches FDA decision on Narsoplimab expected September 25. Narsoplimab's approval could unlock $500-$1B commercial opportunity. Omeros is scaling back other initiatives to focus on Narsoplimab launch. Despite past losses, OMER shares are trending up by 3.58%.
View signal analysis